{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:01:51Z","timestamp":1772121711775,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.vaccine.2022.05.082","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T02:42:12Z","timestamp":1654483332000},"page":"4220-4230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials"],"prefix":"10.1016","volume":"40","author":[{"given":"Mar\u00eda","family":"Eugenia-Toledo-Roman\u00ed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslyhana","family":"Verdecia-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiby","family":"Rodr\u00edguez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rodr\u00edguez-Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Valenzuela-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Paredes-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"S\u00e1nchez-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocmira","family":"P\u00e9rez-Nicado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Gonz\u00e1lez-Mugica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tays","family":"Hern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretchen","family":"Bergado-Baez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franciscary","family":"Pi-Estopi\u00f1\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto","family":"Cruz-Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anitza","family":"Fraga-Quintero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majela","family":"Garc\u00eda-Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Palenzuela-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Bar\u00f3-Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivis","family":"Mendoza-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonsire","family":"Fernandez-Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanet","family":"Climent-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darielys","family":"Santana-Mederos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ubel","family":"Ram\u00edrez Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanelda","family":"Garc\u00eda-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"P\u00e9rez-Mass\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Guang-Wu-Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammy","family":"Boggiano-Ayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Ojito-Magaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yury","family":"Vald\u00e9s-Balb\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Garc\u00eda-Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"V\u00e9rez-Bencomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanet","family":"G\u00f3mez-Maceo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radamet","family":"Reyes-Matienzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Manuel Coviella-Artime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irania","family":"Morffi-Cinta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisel","family":"Mart\u00ednez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismavy","family":"Castillo-Quintana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniurka","family":"Garc\u00e9s-Hechavarr\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Valera-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayle","family":"Mart\u00ednez-Bedoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raine","family":"Garrido-Arteaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e9lix","family":"Cardoso-SanJorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Quintero Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivis","family":"Ontivero-Pino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Teresa P\u00e9rez-Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilin","family":"Morales-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Noa-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivette","family":"Orosa-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianniz","family":"D\u00edaz-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrudis","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaima","family":"Tundidor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Garc\u00eda-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaima","family":"Mu\u00f1oz-Morejon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Galano-Frutos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli\u00e1n","family":"Rodr\u00edguez-Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaylid","family":"Arteaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maite","family":"Medina N\u00e1poles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Espi \u00c1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Fontanies Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.05.082_b0005","unstructured":"WHO Coronavirus (COVID-19) Dashboard, https:\/\/covid19.who.int\/ (Consulted October 20, 2021)."},{"key":"10.1016\/j.vaccine.2022.05.082_b0010","unstructured":"Guidance for Industry: Development and Licensure of Vaccines to Prevent COVID-19, USFDA, June 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/development-andlicensure-vaccines-prevent-covid-19 (Consulted October 20, 2021)."},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.082_b0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2022.05.082_b0020","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"10269","key":"10.1016\/j.vaccine.2022.05.082_b0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.vaccine.2022.05.082_b0030","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"issue":"10275","key":"10.1016\/j.vaccine.2022.05.082_b0035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.vaccine.2022.05.082_b0040","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.082_b0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"issue":"10296","key":"10.1016\/j.vaccine.2022.05.082_b0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey\u201c","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.05.082_b0055","doi-asserted-by":"crossref","unstructured":"Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv https:\/\/doi.org\/10.1101\/2021.06.30.21259439.","DOI":"10.1101\/2021.06.30.21259439"},{"issue":"13","key":"10.1016\/j.vaccine.2022.05.082_b0060","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med DOI"},{"key":"10.1016\/j.vaccine.2022.05.082_b0065","unstructured":"Coronavirus (COVID-19) vaccinations. https:\/\/ourworldindata.org\/covid-vaccinations (Consulted October 15, 2021)."},{"issue":"7867","key":"10.1016\/j.vaccine.2022.05.082_b0070","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/d41586-021-01762-w","article-title":"COVID vaccines to reach poorest countries in 2023 - despite recent pledges","volume":"595","author":"Padma","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.05.082_b0075","unstructured":"COVID-19 \u2013 Landscape of novel coronavirus candidate vaccine development worldwide, September 17, 2021. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines (consulted October 19, 2021)."},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.082_b0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev-med-042420-113212","article-title":"Whole Inactivated Virus and Protein-Based COVID-19 Vaccines","volume":"73","author":"Hotez","year":"2022","journal-title":"Annu Rev Med"},{"issue":"5683","key":"10.1016\/j.vaccine.2022.05.082_b0085","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1126\/science.1095209","article-title":"A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b","volume":"305","author":"Verez-Bencomo","year":"2004","journal-title":"Science"},{"issue":"41","key":"10.1016\/j.vaccine.2022.05.082_b0090","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.1016\/j.vaccine.2014.06.094","article-title":"Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: a randomized phase I clinical trial","volume":"32","author":"Dotres","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.082_b0095","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/acscentsci.1c00216","article-title":"Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines","volume":"7","author":"Valdes-Balbin","year":"2021","journal-title":"ACS Cent Sci"},{"issue":"7","key":"10.1016\/j.vaccine.2022.05.082_b0100","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acschembio.1c00272","article-title":"SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity","volume":"16","author":"Valdes-Balbin","year":"2021","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.vaccine.2022.05.082_b0105","unstructured":"International Clinical Trials Registry Platform. Identifier RPCEC00000340. phase I study, open, sequential and adaptive for evaluating the safety, reactogenicity and explore the immunogenicity of the prophylactic Vaccine candidate FINLAY-FR-2 anti SARSCoV-2 (COVID-19). https:\/\/rpcec.sld.cu\/en\/trials\/RPCEC00000340-En."},{"key":"10.1016\/j.vaccine.2022.05.082_b0110","unstructured":"International Clinical Trials Registry Platform. Identifier RPCEC00000347 phase II study, multicenter and adaptive for evaluating the immunogenicity, safety and reactogenicity of the Anti-SARS Prophylactic Vaccine Candidate - CoV - 2, FINLAY- FR-2 (COVID-19). https:\/\/rpcec.sld.cu\/en\/trials\/RPCEC00000347-En."},{"key":"10.1016\/j.vaccine.2022.05.082_b0115","doi-asserted-by":"crossref","unstructured":"Chang-Monteagudo A, Ochoa-Azze R, Climent-Ruiz Y, Mac\u00edas-Abraham C, Rodr\u00edguez-Noda L, Valenzuela-Silva C et al. A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial. Lancet Reg Health Am 2021;4:100079. https:\/\/doi.org\/10.1016\/j.lana.2021.100079.","DOI":"10.1016\/j.lana.2021.100079"},{"key":"10.1016\/j.vaccine.2022.05.082_b0120","unstructured":"International Clinical Trials Registry Platform. Identifier RPCEC00000366. A phase II, sequential, multicenter, adaptive, parallel groups, randomized, placebo-controlled, double-blinded, to evaluate safety, reactogenicity and immunogenicity of the prophylactic vaccine candidate FINLAY-FR-1A anti SARS-CoV-2, in COVID-19 convalescents. https:\/\/rpcec.sld.cu\/en\/trials\/RPCEC00000366-En."},{"key":"10.1016\/j.vaccine.2022.05.082_b0125","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE): Available: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. (consulted October 19, 2021)."},{"key":"10.1016\/j.vaccine.2022.05.082_b0130","unstructured":"World Health Organization. Causality Assessment of an Adverse Event Following Immunization (AEFI). 2nd Edition. Geneva: WHO; 2018. https:\/\/www.who.int\/publications\/i\/item\/causality-assessment-aefi-user-manual-2019."},{"issue":"8","key":"10.1016\/j.vaccine.2022.05.082_b0135","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10275","key":"10.1016\/j.vaccine.2022.05.082_b0140","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2022.05.082_b0145","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2022.05.082_b0150","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/978-1-62703-992-5_27","article-title":"Fine epitope mapping based on phage display and extensive mutagenesis of the target antigen","volume":"1131","author":"Rojas","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2022.05.082_b0155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/978-1-4939-7447-4_30","article-title":"Phagekines: screening binding properties and biological activity of functional cytokines displayed on phages","volume":"1701","author":"Rojas","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"10","key":"10.1016\/j.vaccine.2022.05.082_b0160","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/jmv.25986","article-title":"Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples","volume":"92","author":"Manenti","year":"2020","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.082_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2249.2000.01109.x","article-title":"Conjugate vaccines","volume":"119","author":"Goldblatt","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2022.05.082_b0170","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Jansen, phase 1\/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: Interim report","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"10249","key":"10.1016\/j.vaccine.2022.05.082_b0175","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5- vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10240","key":"10.1016\/j.vaccine.2022.05.082_b0180","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.082_b0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10249","key":"10.1016\/j.vaccine.2022.05.082_b0190","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.vaccine.2022.05.082_b0195","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2022.05.082_b0200","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s43587-021-00114-7","article-title":"SARS-CoV-2, COVID-19 and the aging immune system","volume":"1","author":"Bartleson","year":"2021","journal-title":"Nat Aging"},{"key":"10.1016\/j.vaccine.2022.05.082_b0205","unstructured":"Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 14. June 3, 2021. Available at: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/991343\/Variants_of_Concern_VOC_Technical_Briefing_14.pdf."},{"issue":"10","key":"10.1016\/j.vaccine.2022.05.082_b0210","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14760584.2021.1976153","article-title":"Impact of the Delta variant on vaccine efficacy and response strategies","volume":"20","author":"Bian","year":"2021","journal-title":"Expert Rev Vaccines"},{"issue":"10293","key":"10.1016\/j.vaccine.2022.05.082_b0215","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.05.082_b0220","unstructured":"G. Guzman. Updated report of the \u201cPedro Kouri\u201d Tropical Medicine Institute on the circulating strains of SARS COVID19 in Havana. Personal communication."},{"issue":"7871","key":"10.1016\/j.vaccine.2022.05.082_b0225","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"issue":"49","key":"10.1016\/j.vaccine.2022.05.082_b0230","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd6160","article-title":"SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection","volume":"5","author":"Altmann","year":"2020","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.082_b0235","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"issue":"7860","key":"10.1016\/j.vaccine.2022.05.082_b0240","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41586-021-01359-3","article-title":"Mix-and-match COVID vaccines trigger potent immune response","volume":"593","author":"Callaway","year":"2021","journal-title":"Nature"},{"issue":"10289","key":"10.1016\/j.vaccine.2022.05.082_b0245","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","article-title":"Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data","volume":"397","author":"Shaw","year":"2021","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:16:38Z","timestamp":1759403798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22007174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":49,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0264410X22007174"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.082","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.14.21266309","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}